Spots Global Cancer Trial Database for Candin Safety & Efficacy Study for the Treatment of Warts

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Candin Safety & Efficacy Study for the Treatment of Warts

Official Title: Study of the Safety and Effectiveness of Candin for the Treatment of Common Warts

Study ID: NCT01757392

Conditions

Warts

Human Papilloma Virus

Interventions

Candida albicans Skin Test Antigen

Study Description

Brief Summary: The primary objective of this study is to determine the safety of Candin® (Candida albicans Skin Test Antigen) at a 0.3 ml dose level at up to 6 monthly injections for treating common warts (Verruca vulgaris).

Detailed Description: The primary objective of this study is to determine the safety of Candin® (Candida albicans Skin Test Antigen) at either 0.3 mL dose levels at up to 6 monthly injections (a maximal, cumulative dose of 1.9 mL, including the delayed-type hypersensitivity (DTH) test) for treating common warts (Verruca vulgaris). A secondary objective is to understand the relative effectiveness of the 0.3 dose level for treating common warts, both those that were injected and those that were not injected as well as other types of warts that were not injected to allow a determination of appropriate dose levels to use in a future dose-ranging efficacy trial.